Log in

Relevant bibliographies by topics / Besifloxacin / Journal articles

To see the other types of publications on this topic, follow the link: Besifloxacin.

Journal articles on the topic 'Besifloxacin'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Besifloxacin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khimdas, S., K. L. Visscher, and C. M. L. Hutnik. "Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis." Ophthalmology and Eye Diseases 3 (January 2011): OED.S4102. http://dx.doi.org/10.4137/oed.s4102.

Full text

Abstract:

Objective To outline the pharmacodynamics, efficacy and safety of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Quality of Evidence MEDLINE database was searched to review recent pharmacodynamic and clinical studies evaluating besifloxacin and comparing besifloxacin to other topical antibiotics for ophthalmic use. Findings were limited to full-text articles from clinical journals in the English language. Main Message Bacterial resistance is a common source for treatment failure in bacterial conjunctivis. Besifloxacin, a novel fourth generation synthetic fluoroquinolone is likely to show lower resistance rates due to its mechanism of action and its short-term use for ocular infections only (decreased systemic exposure). Besifloxacin displays improved pharmacodynamic properties compared to other commonly used fluoroquinolones and has shown to be efficacious and safe in clinical studies. Conclusion Besifloxacin ophthalmic suspension 0.6% provides safe and efficacious treatment for bacterial conjunctivitis. The factors leading to bacterial resistance are diminished, which allows besifloxacin to be a favorable treatment option.

APA, Harvard, Vancouver, ISO, and other styles

2

Haas, Wolfgang, Chris M. Pillar, Gary E. Zurenko, Jacqueline C. Lee, Lynne S. Brunner, and Timothy W. Morris. "Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria." Antimicrobial Agents and Chemotherapy 53, no. 8 (June 8, 2009): 3552–60. http://dx.doi.org/10.1128/aac.00418-09.

Full text

Abstract:

ABSTRACT The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents.

APA, Harvard, Vancouver, ISO, and other styles

3

Blondeau, Joseph, and Heleen DeCory. "In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride." Pharmaceuticals 14, no. 6 (May 27, 2021): 517. http://dx.doi.org/10.3390/ph14060517.

Full text

Abstract:

Background: Besifloxacin ophthalmic suspension 0.6% (w/v%) contains benzalkonium chloride (BAK) as a preservative. We evaluated the in vitro time-kill activity of besifloxacin, alone and in combination with BAK, against common bacteria implicated in ophthalmic infections. Methods: The activity of besifloxacin (100 µg/mL), BAK (10, 15, 20, and 100 µg/mL), and combinations of besifloxacin and BAK were evaluated against isolates of Staphylococcus epidermidis (n = 4), Staphylococcus aureus (n = 3), Haemophilus influenzae (n = 2), and Pseudomonas aeruginosa (n = 2) in time-kill experiments of 180 min duration. With the exception of one S. aureus isolate, all of the staphylococcal isolates were methicillin- and/or ciprofloxacin-resistant; one P. aeruginosa isolate was ciprofloxacin-resistant. The reductions in the viable colony counts (log10 CFU/mL) were plotted against time, and the differences among the time–kill curves were evaluated using an analysis of variance. Areas-under-the-killing-curve (AUKCs) were also computed. Results: Besifloxacin alone demonstrated ≥3-log killing of P. aeruginosa (<5 min) and H. influenzae (<120 min), and approached 3-log kills of S. aureus. BAK alone demonstrated concentration-dependent killing of S. epidermidis, S. aureus and H. influenzae, and at 100 µg/mL produced ≥3-log kills in <5 min against these species. The addition of BAK (10, 15, and 20 µg/mL) to besifloxacin increased the rate of killing compared to besifloxacin alone, with earlier 3-log kills of all species except P. aeruginosa and a variable impact on S. aureus. The greatest reductions in AUKC were observed among H. influenzae (8-fold) and S. epidermidis (≥5-fold). Similar results were found when the isolates were evaluated individually by their resistance phenotype. Conclusions: In addition to confirming the activity of 100 µg/mL BAK as a preservative in the bottle, these data suggest that BAK may help besifloxacin to achieve faster time-kills on-eye in the immediate timeframe post-instillation before extensive dilution against bacterial species implicated in ophthalmic infections, including drug-resistant S. epidermidis. Greater killing activity may help prevent resistance development and/or help treat resistant organisms.

APA, Harvard, Vancouver, ISO, and other styles

4

Saha, Bijit. "UV-HPLC METHOD DEVELOPMENT AND VALIDATION FOR QUANTIFICATION OF BESIFLOXACIN HYDROCHLORIDE." Asian Journal of Pharmaceutical and Clinical Research 10, no. 5 (May 1, 2017): 250. http://dx.doi.org/10.22159/ajpcr.2017.v10i5.17456.

Full text

Abstract:

Objectives: The objective of the present investigation was to develope and validates a new, rapid, accurate high performance liquid chromatographic (HPLC) method for the quantification of Besifloxacin Hydrochloride.Methods: Isocratic UV-HPLC separation was performed using a Zodiac C18 (150 X 4.6 mm) column, with 150 volume of Acetonitrile and 350 mL of Methanol in 500 mL buffer as mobile phase at a flow rate of 2 mL/min and UV detection at 295nm..Results: The sample found stable for 24 hours in analyte solution and compatible with nylon filter. The Beer’s law plots were found to be linear over the concentration range 70% to 130% with a correlation coefficient (r2) 0.9999 in diluent, phosphate buffer and simulated tear media. The %RSD was found less than 2% shows good precision, acceptable accuracy and reproducibility of the new method for the determination of Besifloxacin Hydrochloride.Conclusion: The method was validated as per the ICH guidelines. The method is accurate and can be applied for qualitative analysis of Besifloxacin Hydrochloride in bulk drug and in formulation.Keywords: Besifloxacin hydrochloride, High performance liquid chromatographic, Stress testing, Validation, Linearity, Accuracy, Precision.

APA, Harvard, Vancouver, ISO, and other styles

5

Carter, Natalie J., and Lesley J. Scott. "Besifloxacin Ophthalmic Suspension 0.6%." Drugs 70, no. 1 (January 2010): 83–97. http://dx.doi.org/10.2165/11203820-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

MECHCATIE, ELIZABETH. "Panel Supports Besifloxacin For Bacterial Conjunctivitis." Pediatric News 43, no. 1 (January 2009): 2. http://dx.doi.org/10.1016/s0031-398x(09)70004-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nafziger, A. N., and J. S. Bertino. "Besifloxacin ophthalmic suspension for bacterial conjunctivitis." Drugs of Today 45, no. 8 (2009): 577. http://dx.doi.org/10.1358/dot.2009.45.8.1417975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Attia, Ali K., Amr M. Badawy, and Samr G. Abd-Elhamid. "Determination of sparfloxacin and besifloxacin hydrochlorides using gold nanoparticles modified carbon paste electrode in micellar medium." RSC Advances 6, no. 46 (2016): 39605–17. http://dx.doi.org/10.1039/c6ra04851j.

Full text

Abstract:

Determination of sparfloxacin and besifloxacin hydrochlorides using gold nanoparticles modified carbon paste electrode in micellar medium AuCPE was used to study the electrochemical behavior of SPAR and BESI using CV and DPV in presence of SDS.

APA, Harvard, Vancouver, ISO, and other styles

9

Hussar, Daniel A. "New drugs: Golimumab, besifloxacin hydrochloride, and artemether/lumefantrine." Journal of the American Pharmacists Association 49, no. 4 (July 2009): 570–73. http://dx.doi.org/10.1331/japha.2009.09523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bhatnagar, Shubhmita, Amala Saju, Krishna Deepthi Cheerla, Sudeep Kumar Gade, Prashant Garg, and Venkata Vamsi Krishna Venuganti. "Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles." Drug Delivery and Translational Research 8, no. 3 (December 29, 2017): 473–83. http://dx.doi.org/10.1007/s13346-017-0470-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Wang, Jun-Jie. "Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis." International Journal of Ophthalmology 12, no. 12 (December 18, 2019): 1898–907. http://dx.doi.org/10.18240/ijo.2019.12.13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mahvan, Tracy D., Jaime R. Hornecker, Whitney A. Buckley, and Suzanne Clark. "The Role of Besifloxacin in the Treatment of Bacterial Conjunctivitis." Annals of Pharmacotherapy 48, no. 5 (February 24, 2014): 616–25. http://dx.doi.org/10.1177/1060028014524175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Talamo, Jonathan H., Kathryn M. Hatch, and Emily C. Woodcock. "Delayed Epithelial Closure After PRK Associated With Topical Besifloxacin Use." Cornea 32, no. 10 (October 2013): 1365–68. http://dx.doi.org/10.1097/ico.0b013e31829e1e8c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Chang, Mei H., and Horatio B. Fung. "Besifloxacin: A topical fluoroquinolone for the treatment of bacterial conjunctivitis." Clinical Therapeutics 32, no. 3 (March 2010): 454–71. http://dx.doi.org/10.1016/j.clinthera.2010.03.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Parekh, Jai G., Hunter T. Newsom, and Steven Nielsen. "Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients." Journal of Cataract & Refractive Surgery 38, no. 10 (October 2012): 1864–67. http://dx.doi.org/10.1016/j.jcrs.2012.08.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Waghulde, Vishakha, and Ravindranath Saudagar. "FORMULATION DEVELOPMENT AND EVALUATION OF pH TRIGGERED IN SITU OPHTHALMIC GEL OF BESIFLOXACIN HYDROCHLORIDE." Journal of Drug Delivery and Therapeutics 8, no. 5 (September 10, 2018): 313–21. http://dx.doi.org/10.22270/jddt.v8i5.1874.

Full text

Abstract:

The aim of the present work was to formulation and evaluation of pH Triggered in-situ Ophthalmic Gel of Besifloxacin Hydrochloride to overcome the drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. Carbopol 934 and HPMC K100. Carbopol 934 were used as gelling agent and HPMC K100 were used as bioadhesive polymer. Besifloxacin Hydrochloride shows activity against a wide range of Gram-positive and negative ocular pathogens: examples are Corynebacterium pseudodiphtheriticum, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Streptococcus salivarius. The in situ gelling system involves sol-to-gel transition in the cul-de-sac upon instillation to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations were evaluated for clarity, pH, viscosity, Bioadhesive strength of gel, gel strength gel, Drug Content, In-vitro Drug Release Study, Antibacterial Activity, Isotonicity Evaluation, HET-CAM Test and stability studies. The drug content was in the range of 97-99.57 %. Formulation F5 selected as optimized on the basis of evaluation. It shows highest drug release upto 8hrs. It shows good antibiotic activity against Staphylococcus aureus. The optimized formulation was isotonic with blood cells. It passes sterility test. The optimized formulation passes the ocular irritancy test i.e. HET-CAM Test. The formulation kept for the stability study for 3 months. Short term stability study indicates that room temperature 400±20 was appropriate storage condition for formulations. Keywords: pH Triggered, bioadhesive polymer, Carbopol 934, HPMC K100, HET-CAM Test, Antibacterial Activity.

APA, Harvard, Vancouver, ISO, and other styles

17

Tótoli, Eliane Gandolpho, and Hérida Regina Nunes Salgado. "Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods." Critical Reviews in Analytical Chemistry 48, no. 2 (February 2, 2018): 132–42. http://dx.doi.org/10.1080/10408347.2018.1429885.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Palileo, Coleen, and Mark McDermott. "Confirmation of Besifloxacin Corneal Precipitation After Cataract Surgery by Raman Spectroscopy." Ophthalmology 126, no. 11 (November 2019): 1548. http://dx.doi.org/10.1016/j.ophtha.2019.06.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Haas, Wolfgang, Chris M. Pillar, Christine K. Hesje, Christine M. Sanfilippo, and Timothy W. Morris. "Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae." Journal of Antimicrobial Chemotherapy 65, no. 7 (April 30, 2010): 1441–47. http://dx.doi.org/10.1093/jac/dkq127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bertino, Joseph S., and Jin-Zhong Zhang. "Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis." Expert Opinion on Pharmacotherapy 10, no. 15 (September 10, 2009): 2545–54. http://dx.doi.org/10.1517/14656560903213413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

O’Brien, Terrence P. "Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis." Advances in Therapy 29, no. 6 (June 2012): 473–90. http://dx.doi.org/10.1007/s12325-012-0027-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Deschênes, Jean, and Joseph Blondeau. "Besifloxacin in the management of bacterial infections of the ocular surface." Canadian Journal of Ophthalmology 50, no. 3 (June 2015): 184–91. http://dx.doi.org/10.1016/j.jcjo.2014.12.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kala, Shivani, Prachi Gurudiwan, and Divya Juyal. "Formulation and Evaluation of Besifloxacin Loaded in Situ Gel for Ophthalmic Delivery." UK Journal of Pharmaceutical Biosciences 6, no. 2 (August 1, 2018): 36. http://dx.doi.org/10.20510/ukjpb/6/i2/175583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Proksch, Joel W., Camille P. Granvil, Raphaële Siou-Mermet, Timothy L. Comstock, Michael R. Paterno, and Keith W. Ward. "Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans." Journal of Ocular Pharmacology and Therapeutics 25, no. 4 (August 2009): 335–44. http://dx.doi.org/10.1089/jop.2008.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sanders, Melissa E., Quincy C. Moore, Erin W. Norcross, Afshin Shafiee, and Mary E. Marquart. "Efficacy of Besifloxacin in an Early Treatment Model of Methicillin-ResistantStaphylococcus AureusKeratitis." Journal of Ocular Pharmacology and Therapeutics 26, no. 2 (April 2010): 193–98. http://dx.doi.org/10.1089/jop.2009.0121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Majmudar, Parag A., and Thomas E. Clinch. "Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients." Cornea 33, no. 5 (May 2014): 457–62. http://dx.doi.org/10.1097/ico.0000000000000098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Kumar, G. Pradeep, Vishal Srivastava, Kiran Khandelwal, Rajesh Kumar, S. G. Hiriyanna, Ajay Kumar, and Pramod Kumar. "Simple Isocratic HPLC Method for Determination of Enantiomeric Impurity in Besifloxacin Hydrochloride." Chirality 28, no. 9 (August 26, 2016): 628–32. http://dx.doi.org/10.1002/chir.22626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mah, Francis S., and Christine M. Sanfilippo. "Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections." Ophthalmology and Therapy 5, no. 1 (March 24, 2016): 1–20. http://dx.doi.org/10.1007/s40123-016-0046-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Abd El-Hay, Soad S., and Heba M. El-Sayed. "A High-Throughput Fluorometric Method for Quantitation of Besifloxacin Hydrochloride Using Microplate Reader." Current Pharmaceutical Analysis 14, no. 3 (April 10, 2018): 198–203. http://dx.doi.org/10.2174/1573412913666170126143008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Yu, Xianyong, Bingfei Jiang, Zhixi Liao, Yue Jiao, and Pinggui Yi. "Study on the interaction between Besifloxacin and bovine serum albumin by spectroscopic techniques." Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 149 (October 2015): 116–21. http://dx.doi.org/10.1016/j.saa.2015.04.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Comstock, Timothy L., Michael R. Paterno, Jennifer A. Lynch, Heleen H. DeCory, and Dale W. Usner. "Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in Patients With Bacterial Conjunctivitis." Optometry - Journal of the American Optometric Association 80, no. 6 (June 2009): 297–98. http://dx.doi.org/10.1016/j.optm.2009.04.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Nguyen, Alexander T., Augustine R. Hong, Jeanine Baqai, Anthony J. Lubniewski, and Andrew J. W. Huang. "Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections." Cornea 34, no. 8 (August 2015): 967–71. http://dx.doi.org/10.1097/ico.0000000000000492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sanders, Melissa E., Erin W. Norcross, Quincy C. Moore, Afshin Shafiee, and Mary E. Marquart. "Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis." Cornea 28, no. 9 (October 2009): 1055–60. http://dx.doi.org/10.1097/ico.0b013e31819e34cb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Zhang, Jin-Zhong, Kathleen L. Krenzer, Francisco J. López, and Keith W. Ward. "Comparative effects of besifloxacin and other fluoroquinolones on corneal reepithelialization in the rabbit." Journal of Cataract & Refractive Surgery 36, no. 6 (June 2010): 1049–50. http://dx.doi.org/10.1016/j.jcrs.2010.03.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Donnenfeld, Eric D., Timothy L. Comstock, and Joel W. Proksch. "Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application." Journal of Cataract & Refractive Surgery 37, no. 6 (June 2011): 1082–89. http://dx.doi.org/10.1016/j.jcrs.2010.12.046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Koulenti, Xu, Mok, Song, Karageorgopoulos, Armaganidis, Lipman, and SotiriosTsiodras. "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms." Microorganisms 7, no. 8 (August 18, 2019): 270. http://dx.doi.org/10.3390/microorganisms7080270.

Full text

Abstract:

Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.

APA, Harvard, Vancouver, ISO, and other styles

37

Comstock, Timothy L., Michael R. Paterno, Heleen H. DeCory, and Dale W. Usner. "Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis." Clinical Drug Investigation 30, no. 10 (October 2010): 675–85. http://dx.doi.org/10.2165/11536720-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ascioglu, S., M. Akova, and D. Kaya. "PIN52 CAN BESIFLOXACIN USE DECREASE BACTERIAL CONJUNCTIVITIS BURDEN? - AN ESTIMATION VIA DYNAMIC TRANSMISSION MODELLING." Value in Health 23 (May 2020): S177. http://dx.doi.org/10.1016/j.jval.2020.04.520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Proksch, Joel W., and Keith W. Ward. "Ocular Pharmacokinetics/Pharmacodynamics of Besifloxacin, Moxifloxacin, and Gatifloxacin Following Topical Administration to Pigmented Rabbits." Journal of Ocular Pharmacology and Therapeutics 26, no. 5 (October 2010): 449–58. http://dx.doi.org/10.1089/jop.2010.0054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Tótoli, Eliane Gandolpho, and Hérida Regina Nunes Salgado. "Miniaturized turbidimetric assay: A green option for the analysis of besifloxacin in ophthalmic suspension." Talanta 209 (March 2020): 120532. http://dx.doi.org/10.1016/j.talanta.2019.120532.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Zhang, Jin-Zhong, Megan E. Cavet, and Keith W. Ward. "Anti-Inflammatory Effects of Besifloxacin, a Novel Fluoroquinolone, in Primary Human Corneal Epithelial Cells." Current Eye Research 33, no. 11-12 (January 2008): 923–32. http://dx.doi.org/10.1080/02713680802478704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Comstock, Timothy L., Michael R. Paterno, Jennifer A. Lynch, Heleen H. DeCory, and Dale W. Usner. "Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Pediatric Patients With Bacterial Conjunctivitis." Optometry - Journal of the American Optometric Association 80, no. 6 (June 2009): 296–97. http://dx.doi.org/10.1016/j.optm.2009.04.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ramisetti, Nageswara Rao, Manikanta Swamy Arnipalli, Narendra Varma Nimmu, and Ramachandra Bondigalla. "UHPLC Determination of Besifloxacin Enantiomers on Immobilized Amylose Tris(3,5-dichlorophenylcarbamate) Chiral Stationary Phase." Chromatographia 80, no. 10 (July 19, 2017): 1509–15. http://dx.doi.org/10.1007/s10337-017-3346-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Baig, Mirza Salman, Hamza Owida, Wanjiku Njoroge, Aquil-ur-Rahim Siddiqui, and Ying Yang. "Development and evaluation of cationic nanostructured lipid carriers for ophthalmic drug delivery of besifloxacin." Journal of Drug Delivery Science and Technology 55 (February 2020): 101496. http://dx.doi.org/10.1016/j.jddst.2019.101496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Comstock, Timothy L., Michael R. Paterno, Dale W. Usner, and Michael E. Pichichero. "Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Children and Adolescents with Bacterial Conjunctivitis." Pediatric Drugs 12, no. 2 (April 2010): 105–12. http://dx.doi.org/10.2165/11534380-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Costa, Márcia C. N., Amanda T. Barden, Juliana M. M. Andrade, Tércio P. Oppe, and Elfrides E. S. Schapoval. "Quantitative evaluation of besifloxacin ophthalmic suspension by HPLC, application to bioassay method and cytotoxicity studies." Talanta 119 (February 2014): 367–74. http://dx.doi.org/10.1016/j.talanta.2013.10.051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Schechter, Barry A., Jai G. Parekh, and William Trattler. "Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Keratitis: A Retrospective Safety Surveillance Study." Journal of Ocular Pharmacology and Therapeutics 31, no. 2 (March 2015): 114–21. http://dx.doi.org/10.1089/jop.2014.0039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cambau, E., S. Matrat, X. S. Pan, R. Roth Dit Bettoni, C. Corbel, A. Aubry, C. Lascols, J. Y. Driot, and L. M. Fisher. "Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli." Journal of Antimicrobial Chemotherapy 63, no. 3 (January 15, 2009): 443–50. http://dx.doi.org/10.1093/jac/dkn528.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Meena, Dr Ravindra Kumar, and Dr M. L. Gupta. "Clinical comparison of 0.6% besifloxacin ophthalmic suspension and 1.5% azithromycin ophthalmic suspension in acute bacterial conjunctivitis." International Journal of Medical Research and Review 3, no. 11 (December 31, 2015): 1288–93. http://dx.doi.org/10.17511/ijmrr.2015.i11.234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Miller, Darlene, Jonathan S. Chang, Harry W. Flynn, and Eduardo C. Alfonso. "Comparative In Vitro Susceptibility of Besifloxacin and Seven Comparators Against Ciprofloxacin- and Methicillin-Susceptible/Nonsusceptible Staphylococci." Journal of Ocular Pharmacology and Therapeutics 29, no. 3 (April 2013): 339–44. http://dx.doi.org/10.1089/jop.2012.0081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!